AR069009A1 - Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina - Google Patents
Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosinaInfo
- Publication number
- AR069009A1 AR069009A1 ARP080104625A ARP080104625A AR069009A1 AR 069009 A1 AR069009 A1 AR 069009A1 AR P080104625 A ARP080104625 A AR P080104625A AR P080104625 A ARP080104625 A AR P080104625A AR 069009 A1 AR069009 A1 AR 069009A1
- Authority
- AR
- Argentina
- Prior art keywords
- arylindenopirimidins
- adenosine
- antagonists
- receptor
- compound
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98224707P | 2007-10-24 | 2007-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069009A1 true AR069009A1 (es) | 2009-12-23 |
Family
ID=40091927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104625A AR069009A1 (es) | 2007-10-24 | 2008-10-23 | Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8017614B2 (enExample) |
| EP (1) | EP2217575A1 (enExample) |
| JP (1) | JP2011500819A (enExample) |
| CN (1) | CN101835759A (enExample) |
| AR (1) | AR069009A1 (enExample) |
| AU (1) | AU2008317034A1 (enExample) |
| CL (1) | CL2008003131A1 (enExample) |
| PA (1) | PA8801501A1 (enExample) |
| PE (1) | PE20091344A1 (enExample) |
| TW (1) | TW200934493A (enExample) |
| UY (1) | UY31420A1 (enExample) |
| WO (1) | WO2009055308A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110105540A1 (en) * | 2009-10-29 | 2011-05-05 | Jackson Paul F | 2-AMINO-9-[4-(4-METHOXY-PHENOXY)-PIPERIDIN-1-YL]-4-PHENYL-INDENO[1,2-D]PYRIMIDIN-5-ONE AND ITS USE AS A HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONIST |
| US9238643B2 (en) | 2010-09-06 | 2016-01-19 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Amide compounds |
| US9387212B2 (en) | 2012-04-20 | 2016-07-12 | Ucb Biopharma Sprl | Methods for treating Parkinson's disease |
| AU2020205753B2 (en) | 2019-01-11 | 2025-05-29 | Omeros Corporation | Methods and compositions for treating cancer |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127510A1 (en) | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
| WO2005042500A1 (en) | 2003-10-03 | 2005-05-12 | Ortho-Mcneil Pharmaceutical, Inc. | Arylindenopyridines and arylindenopyridines and their use as adenosine a2a receptor antagonist |
-
2008
- 2008-10-17 WO PCT/US2008/080256 patent/WO2009055308A1/en not_active Ceased
- 2008-10-17 CN CN200880112882A patent/CN101835759A/zh active Pending
- 2008-10-17 US US12/253,358 patent/US8017614B2/en not_active Expired - Fee Related
- 2008-10-17 EP EP08841238A patent/EP2217575A1/en not_active Withdrawn
- 2008-10-17 AU AU2008317034A patent/AU2008317034A1/en not_active Abandoned
- 2008-10-17 JP JP2010531141A patent/JP2011500819A/ja not_active Withdrawn
- 2008-10-23 PE PE2008001819A patent/PE20091344A1/es not_active Application Discontinuation
- 2008-10-23 CL CL2008003131A patent/CL2008003131A1/es unknown
- 2008-10-23 AR ARP080104625A patent/AR069009A1/es not_active Application Discontinuation
- 2008-10-23 PA PA20088801501A patent/PA8801501A1/es unknown
- 2008-10-23 TW TW097140560A patent/TW200934493A/zh unknown
- 2008-10-24 UY UY31420A patent/UY31420A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8017614B2 (en) | 2011-09-13 |
| TW200934493A (en) | 2009-08-16 |
| PE20091344A1 (es) | 2009-09-24 |
| CL2008003131A1 (es) | 2010-02-19 |
| EP2217575A1 (en) | 2010-08-18 |
| US20090111827A1 (en) | 2009-04-30 |
| AU2008317034A1 (en) | 2009-04-30 |
| UY31420A1 (es) | 2009-04-30 |
| WO2009055308A1 (en) | 2009-04-30 |
| PA8801501A1 (es) | 2009-05-15 |
| CN101835759A (zh) | 2010-09-15 |
| JP2011500819A (ja) | 2011-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011198A (es) | Derivados de sulfonamida | |
| UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
| CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| CL2011001263A1 (es) | Compuestos derivados de pirimidinonas opcionalmente sustituidas; composicion farmaceutica que los comprende; y su uso como inhibidores de fosfodiesterasa 1 (pde1) para el tratamiento de enfermedades que involucran trastornos de la trayectoria intracelular del receptor de dopamina d1 como parkinson, alzheimer, depresion, enfermedad bipolar, hipertension, glaucoma. | |
| UY31048A1 (es) | Nuevos compuestos de pirimidina y usos de los mismos | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| CL2012002497A1 (es) | Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras. | |
| UY30141A1 (es) | Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato | |
| AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| AR060651A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales | |
| SV2010003580A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| CL2008001636A1 (es) | Compuestos derivados de bencimidazol, antagonistas de los receptores de angiotensina ii de tipo 1; proceso de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica de los compuestos; y su uso para tratar la hipertension, insuficiencia cardiaca. | |
| SV2009003389A (es) | Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
| ECSP088265A (es) | Derivados de carboxamida como antagonistas del receptor muscarínico | |
| CR10497A (es) | Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38 | |
| UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
| CR10963A (es) | Compuestos de 2-amino pirimidina | |
| CR9722A (es) | Derivados de benzilpiperazina y su uso medico | |
| AR069009A1 (es) | Arilindenopirimidinas y su uso como antagonistas del receptor a₂a de adenosina | |
| UY29735A1 (es) | Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos | |
| CR8270A (es) | Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |